tirzepatide and afib Could Have Clinical Utility in Managing Atrial Fibrillation? Bridging the gap between GLP1-receptor

Taken together, the figure highlights a key mechanistic principle underlying the therapeutic rationale for multi-agonist strategies: while GLP-1R monotherapy achieves meaningful metabolic and hepatic benefits exclusively through indirect, systemic pathways, the addition of GIPR and - most importantly - GCGR co-agonism introduces complementary and increasingly direct hepatic mechanisms, providing the pharmacological basis for the superior efficacy observed with dual and triple agonists in MASLD/MASH

While conventional NMN can have a large effect on NAD+ levels, liposomal NMN can act faster, more efficiently and with sustained release for a longer lasting effect

Tambin est indicado para reducir el riesgo de eventos cardiovasculares adversos mayores en adultos con sobrepeso u obesidad y enfermedad cardiovascular establecida

A really good data there and Im really interested what Dons gonna think